Home

CELLTech™

Our proprietary technology, CELLTech™ DBS, is a deep brain stimulation platform with a first clinical indication to improve motor function in patients with permanent, moderate to severe disability due to subcortical ischemic stroke. CELLTech™ requires the same surgical procedure as the FDA-approved deep brain stimulator and as other DBS systems, applies microcurrents directly to brain tissue.

Learn More
CELLTech™ has similarities to other DBS devices that have been safely used for over 30 years for other neurological indications. The primary difference is that the CELLTech™ platform harnesses a proprietary waveform that has been extensively studied for its ability to treat the root cause of many neurological diseases
Our team, including our Medical Committee consisting of renowned physicians around the country, have been working closely with the FDA since 2018 to ensure CELLTech™ will be both safe and effective for human use.

Before Therapy

To qualify for CELLTech™ therapy, an individual must have experienced an ischemic stroke, have lasting significant motor function impairment due to the stroke, be left dependent on others for normal daily routines and personal care due to physical disability caused by the stroke, and meet all other inclusion and exclusion criteria required by the FDA.

During Therapy

CELLTech™ requires the same surgical procedure as the FDA-aproved deep brain stimulator (DBS). During the procedure, very small leads are carefully implanted to targeted regions of the brain that will aid in recovery. Once recovered from the procedure, CELLTech™ therapy is turned on, applying micro current to subcortical brain tissue.

After Therapy

CELLTech™ has been designed to aid the brain in healing properly after a stroke. The main goals of CELLTech™ therapy, therefore, are improvement in motor function, activities of daily living (ADLs) and overall quality of life.

Next Generation Stroke Treatment

"The CELLTech™ technology will potentially reverse or modify the deficits from strokes in a large number of people worldwide. The potential economically and socially is huge; but mostly it's really going to improve a whole lot of lives, which is the exciting part about it."

Dr. Allan Bernstein, MD, Neurology

Director, Sonoma West Hospital

“All of us at Juno Biomedical, Inc. are genuinely passionate about what we do. We live in a time when scientific and medical breakthroughs are happening faster than ever, and our team is excited to be a part of this forward progress. We are on the precipice of bringing a medical device that could potentially repair damaged brain tissue for the first time in history to the thousands, or even millions, in need. That’s exciting!”

Trisha Pfluger, M.S., PMP

Founder and President

“Stroke destroyed the quality of life my mother had. But with CELLTech™ there’s a future. There’s a brightness where before there was no light. With this device, she would have had those years back.”

Rosemary Ward

Daughter of Stroke Victim

Designed by a Team of Industry Leaders and Subject Matter Experts

CELLTech™, our patented medical device technology, represents a groundbreaking approach in the safe and effective treatment of subacute ischemic stroke. Developed by our extraordinary team of R&D industry leaders and subject matter experts, this innovation stands at the forefront of medical device advancement. For further insights into the minds behind CELLTech™, we invite you to visit our About Us page.